The effects of Fushen Granule on the composition and function of the gut microbiota during Peritoneal Dialysis–Related Peritonitis

Lin, Wei; Jiang, Chen; Yu, Hangxing; Wang, Lingling; Li, Jiaqi; Liu, Xinyue; Wang, Lingyun; Yang, Hongtao

doi:10.1016/j.phymed.2021.153561

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zicuiyin decoction, which had better efficacy in improving and protecting kidney function in diabetic kidney disease (DKD) patients, could decline eGFR and ameliorate gut microbiota dysbiosis in a multicenter, parallel-control, open-label, randomized clinical trial ( Liu et al, 2022 ). Fushen Granule (FSG) ameliorated BUN and Scr and improved albumin (ALB) by enriching beneficial bacteria associated with metabolism in patients with peritoneal dialysis-related peritonitis (PDRP) in a randomized controlled trial ( Lin W. et al, 2021 ). Supplementation of amylose resistant starch HAM-RS2 (20 g/d resistant starch) led to an improvement of constipation severity and renal function, elevation in Faecalibacterium , and a decrease in serum urea, IL-6, TNF-α, and Malondialdehyde (MDA) of systemic inflammation in hemodialysis (HD) patients ( Tayebi Khosroshahi et al, 2018 ; Laffin et al, 2019 ; Jia et al, 2021 ).…”

Section: Clinical Trialmentioning

confidence: 99%

Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation

et al. 2023

View full text Add to dashboard Cite

Dysbiosis of gut microbiota plays a fundamental role in the pathogenesis and development of chronic kidney disease (CKD) and its complications. Natural products from plants and microorganisms can achieve recognizable improvement in renal function and serve as an alternative treatment for chronic kidney disease patients with a long history, yet less is known on its beneficial effects on kidney injury by targeting the intestinal microbiota. In this review, we summarize studies on the effects of natural products from plants and microorganisms, including herbal medicines and their bioactive extracts, polysaccharides from plants and microorganisms, and phytochemicals, on the prevention and treatment of chronic kidney disease through targeting gut microflora. We describe the strategies of these anti-CKD effects in animal experiments including remodulation of gut microbiota structure, reduction of uremic toxins, enhancement of short-chain fatty acid (SCFA) production, regulation of intestinal inflammatory signaling, and improvement in intestinal integrity. Meanwhile, the clinical trials of different natural products in chronic kidney disease clinical practice were also analyzed and discussed. These provide information to enable a better understanding of the renoprotective effects of these effective natural products from plants and microorganisms in the treatment of chronic kidney disease. Finally, we propose the steps to prove the causal role of the intestinal microflora in the treatment of chronic kidney disease by natural products from plants and microorganisms. We also assess the future perspective that natural active products from plants and microorganisms can beneficially delay the onset and progression of kidney disease by targeting the gut flora and highlight the remaining challenges in this area. With the continuous deepening of studies in recent years, it has been proved that gut microbiota is a potential target of natural active products derived from plants and microorganisms for chronic kidney disease treatment. Fully understanding the functions and mechanisms of gut microbiota in these natural active products from plants and microorganisms is conducive to their application as an alternative therapeutic in the treatment of chronic kidney disease.

show abstract